Statistics for Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
Total visits
views | |
---|---|
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC | 2 |
Total visits per month
views | |
---|---|
September 2024 | 0 |
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
File Visits
views | |
---|---|
java.util.UUID:2c39efa2-aa93-41a2-b4e1-aaff18d39461 | 25 |
java.util.UUID:2ae12be5-2a3a-46e8-b3a4-938d91a1cf59 | 10 |
java.util.UUID:ada99203-60a1-49cd-b5e9-7c140a5a0ea5 | 10 |
Evans2022Augmenting-CCBY.pdf | 5 |
Top country views
views | |
---|---|
United States | 2 |
Top city views
views | |
---|---|
Franklin | 2 |